Predicting tumor failure in prostate carcinoma after definitive radiation therapy: Limitations of models based on prostate-specific antigen, clinical stage, and Gleason score

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2476-2484

  Vollmer, Robin T ^a,b   Montana, Gustavo S ^a,b,c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Moore Regional Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0032874398     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Andriole, G. L. Serum prostate-specific antigen: the most useful tumor marker. J. Clin. Oncol., 10: 1205-1207, 1992.
2. Epstein, J. I., Walsh, P. C., and Brendler, C. B. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins Experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J. Urol., 152: 1721-1729, 1994.
3. Epstein, J. I., Walsh, P. C., Carmichael, M., and Brendler, C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J. Am. Med. Assoc., 271: 368-374, 1994.
4. Dugan, J. A., Bostwick, D. G., Myers, R. P., Qian, J., Bergstraih, E. J., and Oesterling, J. E. The definition and preoperative prediction of clinically insignificant prostate cancer. J. Am. Med. Assoc., 275: 288-294, 1996.
5. Terris, M. K., McNeal, J. E., and Stamey, T. A. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol., 148: 829-832, 1992.
6. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., and Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
7. Partin, A. W., Kattan, M. W., Subong, E. N. P., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T., and Pearson, J. D. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update. J. Am. Med. Assoc., 277: 1445-1451, 1997.
8. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N., and Lowe, B. A. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845-1850, 1993.
9. Irwin, M. B., and Trappasso, J. G. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology, 44: 862-868, 1994.
10. Dietrick, D. D., McNeal, J. E., and Stamey, T. A. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987-992, 1995.
11. Cupp, M. R., Bostwick, D. G., Myers, R. P., and Oesterling, J. E. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol., 153: 1543-1548, 1995.
12. Terris, M. K., Haney, D. J., Johnstone, I. M., McNeal, J. E., and Stamey, T. A. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology, 45: 75-80, 1995.
13. Peller, P. A., Young, D. C., Marmaduke, D. P., Marsh, W. L., and Badalament, R. A. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer (Phila.), 75: 530-538, 1995.
14. Badalament, R. A., Miller, M. C., Peller, P. A., Young, D. C., Bahn, D. K., Kochic, P., O'Dowd, G. J., and Vetri, R. W. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J. Urol., 156: 1275-1380, 1996.
15. Huland, H., Hammerer, P., Henke, R., and Huland, E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostate carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J. Urol., 155: 1344-1347, 1996.
16. Ravery, V., Schmid, H., Toublanc, M., and Boccon-Gibod, L. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate cancer? Cancer (Phila.), 78: 1079-1084, 1996.
17. Goto, Y., Ohori, M., Arakawa, A., Kattan, M. W., Wheeler, T. M., and Scardino, P. T. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol., 156: 1059-1063, 1996.
18. D'Amico, A. V., Chang, H., Holupka, E., Renshaw, A., Desjardin, A., Chen, M., Loughlin, K. R., and Richie, J. P. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology, 49: 385-391, 1997.
19. D'Amico, A. F., Whittington, R., Malkowicz, S. B., Schnall, M., Tomaszewski, J., Schultz, D., Kao, G., Vanarsdalen, K., and Wein, A. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys., 30: 292-302, 1994.
20. Russell, K. J., Dunatov, C., Hafermann, M. D., Griffeth, J. T., Polissar, L., Pelton, J., Cole, S. B., Taylor, E. W., Wiens, L. W., Koh, W. J., Austin-Seymour, M. M., Griffin, B., Russell, A. H., Laramore, G. E., and Griffin, T. W. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol., 146: 1046-1052, 1991.
21. Ritter, M. A., Messing, E. M., Shanahan, T. G., Potts, S., Chappell, R. J., and Kinsella, T. J. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol., 10: 1208-1217, 1992.
22. Kaplan, I. D., Cox, R. S., and Bagshaw, M. A. Prostate specific antigen after external beam radiotherapy for prostate cancer: followup. J. Urol., 149: 519-522, 1993.
23. Zeitman, A. L., Coen, J. J., Shipley, W. U., Willett, C. G., and Efird, J. T. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol., 757: 640-645, 1994.
24. Chauvet, B., Felix-Faure, C., Lupsascka, N., Fijuth, J., Brewer, Y., Davin, J-L., Kirscher, S., and Reboul, F. Prostate specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. J. Clin. Oncol., 12: 1402-1407, 1994.
25. Leibel, S. A., Zelefsky, M. J., Kutcher, G. J., Burman, C. M., Mohan, R., Mageras, G. S., Ling, C. C., and Fuks, Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin. Oncol., 21: 580-597, 1994.
26. Kuban, D. A., El-Mahdi, A. M., and Schellhammer, P. F. Prostate specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 32: 307-316, 1995.
27. Crook, J. M., Bahadur, Y. A., Bociek, R. G., Perry, G. A., Robertson, S. J., and Esche, B. A. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer (Phila.), 79: 328-336, 1997.
28. Zagars, G. K., Pollack, A., and von Eschenbach, A. C. Prognostic factors for clinically localized prostate carcinoma. Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer (Phila.), 79: 1370-1380, 1997.
29. Movsas, B., Hanlon, A. L., Teshima, T., and Hanks, G. E. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer (Phila.), 80: 1093-1102, 1997.
30. Pisansky, T. M., Kahn, M. J., and Bostwick, D. G. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer (Phila.), 79: 2154-2161, 1997.
31. Ben-Josef, E., Shamsa, F., and Forman, J. D. Predicting the outcome of radiotherapy for prostate carcinoma. A model building strategy. Cancer (Phila.), 82: 1334-1342, 1998.
32. Green, G. A., Hanlon, A. L., Al-Saleem, T., and Hanks, G. E. A Gleason socre of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer (Phila.), 83: 971-976, 1998.
33. D'Amico, A. V., and Propert, K. J. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 35: 273-279, 1996.
34. D'Amico, A. V., Whittington, R., Kaplan, I., Beard, C., Schultz, D., Malkowicz, S. B., Wein, A., Tomaszewski, J. E., and Coleman, C. N. Calculated prostate carcinoma volume. The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. Cancer (Phila.), 82: 334-341, 1998.
35. D'Amico, A. V., Desjardin, A., Chung, A., Chen, M-H., Schultz, D., Whittington, R., Malkowicz, S. B., Wein, A., Tomaszewski, J. E., Renshaw, A. A., Loughlin, K., and Richie, J. P. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer (Phila.), 82: 1887-1896, 1998.
36. D'Amico, A. V., Desjardin, A., Chen, M-H., Schultz, D., Renshaw, A. A., Loughlin, K. R., and Richie, J. P. Analyzing the outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer (Phila.), 83: 2172-2180, 1998.
37. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E., and Vessella, R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873-879, 1989.
38. Hosmer, D. W., and Lemeshow, S. Applied logistic regression. New York: John Wiley and Sons, 1989.
39. Vollmer, R. T. Multivariate statistical analysis for pathologists. Part 1. The logistic model. Am. J. Clin. Pathol., 105: 115-126, 1996.
40. McCullah, P., and Neider, J. A. Generalized linear models, Ed. 2. London: Chapman and Hall, 1989.
41. Kattan, M. W., Stapleton, A. M. F., Wheeler, T. M., and Scardino, P. T. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer (Phila.), 79: 528-537, 1997.
42. Vollmer, R. T., Keetch, D. W., and Humphrey, P. A. Predicting the pathology results of radical prostatectomy from preoperative information. A validation study. Cancer (Phila.), 83: 1567-1580, 1998.
43. Chan, L. W., and Stamey, T. A. Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations. J. Urol., 159: 1998-2003, 1998.
44. Cox, D. R., and Oakes, D. Analysis of survival data. London: Chapman and Hall, 1984.
45. Vollmer, R. T. Multivariate statistical analysis for anatomic pathology. Part II: Failure time analysis. Am. J. Clin. Pathol., 106: 522-534, 1996.
46. Hermanek, P., Hutter, R. V. P., Sobin, L. H., and Wagner, G. (eds.). International Union Against Cancer. TNM Atlas, Ed. 4., pp. 272-280. Berlin: Springer-Verlag, 1997.
47. Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol., 23: 272-279, 1992.
48. Venables, W. N., and Ripley, B. D. Modern applied statistics with S-Plus, pp. 283-284. New York: Springer-Verlag, 1994.
49. Narayan, P., Gajendran, V., Taylor, S. P., Tewari, A., Presti, J. C., Leidich, R., Lo, R., Palmer, K., Shinohara, K., and Spaulding, J. T. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology, 46: 205-212, 1995.
50. Egan, A. J. M., and Bostwick, D. G. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am. J. Surg. Pathol., 21: 1496-1500, 1997.
51. Bassily, N. H., Pienta, K. J., and Wojno, K. J. The proportion of Gleason pattern 4 prostatic adenocarcinoma significantly determines risk of postoperative PSA recurrence. Mod. Pathol., 12: 89A, 1999.
52. Herman, C. M., Kattan, M. W., Scardino, P. T., and Wheeler, T. W. Predominant Gleason pattern is a significant predictor of disease progression in Gleason score 7 prostate cancer. Mod. Pathol., 12: 97A, 1999.
53. McNeal, J. E., Viller, A. A., Redwin, E. A., Freiha, F. S., and Stamey, T. A. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (Phila.), 66: 1225-1233, 1990.
54. Herman, C. M., Kattan, M. W., Scardino, P. T., and Wheeler, T. W. Quantification of high grade tumor is a predictor of disease progression in pT3N0 prostate cancer. Mod. Pathol., 12: 97A, 1999.
55. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511-1516, 1996.
56. Moul, J. W., Bettencourt, M-C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Bauer, J. J. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 1559-1567, 1996.
57. Stricker, H. J., Jay, J. K., Linden, M. D., Tamboli, P., and Amin, M. B. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology, 47: 366-369, 1996.
58. Theodorescu, D., Broder, S. R., Boyd, J, C., Mills, S. E., and Frierson, H. F. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol., 158: 131-137, 1997.
59. Bubendorf, L., Tapia, C., Gasser, T. C., Casella, R., Grander, B., Moch, H., Mihatsch, M. J., and Sauter, G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum. Pathol., 29: 949-954, 1998.
60. Uzoaru, I., Rubenstein, M., Mirochnik, Y., Slobodskoy, L., Shaw, M., and Guinan, P. An evaluation of markers p53 and Ki-67 for their predictive value in prostate cancer. J. Surg. Oncol., 67: 33-37, 1998.
61. Scalzo, D. A., Kallakury, B. V. S., Gaddipati, R. V., Sheehan, C. E., Keys, H. M., Savage, D., and Ross, J. S. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostate adenocarcinomas. Am. J. Clin. Pathol., 109: 163-168, 1998.
62. Stapleton, A. M. F., Zbell, P., Kattan, M. W., Yang, G., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (Phila.), 82: 168-175, 1998.
63. Keshgegian, A. A., Johnston, E., and Cnaan, A. Bcl-2 oncoprotein positivity and high mib-1 (Ki-67) proliferation rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol., 110: 443-449, 1998.
64. Yang, R. M., Naitoh, J., Murphy, M., Wang, H-J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
65. Kipl levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst., 90: 916-920, 1998.
66. Kipl in prostatic adenocarcinoma. Mod. Pathol., 11: 324-328, 1998.
67. Kipl gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst., 90: 1284-1291, 1998.
68. Partin, A. W., Carger, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R.C., Weber, J. P., and Walsh, P. C. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747-752, 1990.
69. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M., and Scardino, P. T. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol., 151: 1558-1564, 1994.
70. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zincke, H., and Oesterling, J. E. Combining prostate specific antigen with cancer and gland volume to predict more reliably stage: the influence of prostate specific antigen density. J. Urol., 151: 1563-1570, 1994.
71. Cornud, F., Belin, X., Flam, T., Chretien, Y., Deslignieres, S., Paraf, F., Casanova, J. M., Thiounn, N., Helenon, O., Debre, B., Dufour, B., and Moreau, J. F. Local staging of prostate cancer by endorectal MRI using fast spin-echo sequences: prospective correlation with pathological findings after radical prostatectomy. Br. J. Urol., 77: 843-850, 1996.
72. Bartolozzi, C., Menchi, I., Lencioni, R., Serni, S., Lapini, A., Barbanti, G., Bozza, A., Amorosi, A., Manganelli, A., and Carini, M. Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur. Radiol., 6: 339-345, 1996.
73. Perrotti, M., Kaufman, R. P., Jr., Jennings, T. A., Thaleer, H. T., Soloway, S. M., Rifkin, M. D., Fisher, H. A. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol, 156: 106-109, 1996.
74. Bates, T. S., Gillatt, D. A., Cavanagh, P. M., Speakman, M. A comparison of endorectal magnetic resonance imaging and transrectai ultrasonography in the local staging of prostate cancer with histopathologic correlation. Br. J. Urol., 79: 927-932, 1997.
75. Lencioni, R., Menchi, I., Paolicchi, A., Carini, M., Amorosi, A., and Bartolozzi, C. Prediction of pathological tumor volume in clinically localized prostate cancer: value of endorectal coil magnetic resonance imaging. Magma, 5: 117-121, 1997.
76. Ikonen, S., Karkkainen, P., Kivisaari, L., Salo, J. O., Taari, K., Vehmas, T., Tervahartiala, P., Rannikko, S. Magnetic resonance imaging of clinically localized prostatic cancer. J. Urol., 159: 915-919, 1998.
77. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. E., and Wein, A. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology, 49 (Suppl. 3A): 23-30, 1997.